What You Should Know:
– Quibim, a leading healthtech company pioneering the use of imaging biomarkers for precision medicine, announced today the close of its $50 million Series A financing.
– The company has experienced remarkable growth in the number of patients analyzed by its products over the past year. Driven by several regulatory approvals and global commercial partnerships, patient analysis surged by 168% quarter-on-quarter.
Quibim: Advancing Precision Medicine Through AI-Powered Imaging
Quibim is a pioneering healthtech company transforming medical imaging into actionable insights to enhance patient outcomes. By developing advanced imaging biomarkers, Quibim drives innovation in oncology, immunology, and neurology, enabling precise disease characterization and outcome prediction. Leveraging MRI, CT, and PET imaging, the company creates regulatory-cleared medical devices seamlessly integrated into healthcare workflows worldwide. With over 170 installations across leading institutions such as Mass General Brigham and Stanford, Quibim bridges the gap between research, clinical practice, and drug development.
AI-Driven Imaging Solutions
Quibim’s suite of AI-powered imaging solutions includes:
- QP-Prostate: AI-powered lesion detection for enhanced prostate cancer diagnosis; CE, UKCA marked, and 510(k) cleared.
- QP-Brain: Quantification software for early-stage neurological disease, detecting brain atrophy and lesions; CE, UKCA marked, and 510(k) cleared.
- QP-Liver: Automated MR-based diagnosis of diffuse liver diseases through precise fat and iron quantification; CE and UKCA marked.
- QP-Insights: A multi-omics data management and analytics platform, used by global biopharmaceutical companies and research consortiums, including the European Cancer Imaging Initiative. It manages the world’s largest imaging datasets, exceeding 100 million medical images.
Driving Global Expansion and Strategic Partnerships
With a strong international presence, Quibim collaborates with leading healthcare and pharmaceutical organizations to advance imaging science. The company has secured regulatory approvals across the US, EU, UK, and other regions, reinforcing its role as a global leader. Key partnerships include:
- Philips: Integration of AI models into MR scanners for enhanced imaging and reporting.
- Merck KGaA: Development of imaging biomarker models to predict cancer patients’ responses to immunotherapy.
- Novartis: Strategic alliance to drive imaging innovation in drug development.
Vision for the Future: Human Digital Twins
Quibim is committed to achieving a non-invasive, comprehensive understanding of every tissue in the human body at any moment in time. By developing foundational AI models for imaging, the company enables precise phenotyping and predictive analytics across multiple medical domains, including oncology, immunology, neurology, and metabolic disorders. The ultimate goal is to create human digital twins—dynamic models that enhance patient stratification, improve drug development success rates, and enable pre-treatment testing. Current efforts focus on digital twins at the organ and lesion level, exemplified by QP-Brain, QP-Prostate, and QP-Liver. As imaging data volume grows, Quibim aims to extend its models to analyze the entire body, driving a paradigm shift in healthcare.
Series A Financing and U.S. Expansion
Quibim’s latest Series A funding, led by Asabys, Buenavista Equity Partners, UI Investissements, and GoHub Ventures, with participation from existing investors such as Amadeus Capital Partners, APEX Ventures, Partech, Adara Ventures, Leadwind, Tony Fadell’s Build Collective, and Dr. Jonathan Milner, supports the company’s expansion into the U.S. This growth includes:
- Establishing strategic collaborations with hospitals and pharmaceutical companies.
- Enhancing clinical trials through AI-powered imaging solutions.
- Accelerating drug development by leveraging imaging biomarkers for precise, data-driven insights.
Transforming Healthcare Through AI and Imaging
Quibim’s mission is to make imaging a cornerstone of precision medicine, empowering healthcare providers and researchers with cutting-edge AI solutions. By merging imaging technologies, computing, and AI, Quibim is catalyzing a revolutionary shift in healthcare, shaping the future of diagnostics, treatment planning, and drug development.
